Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Biomarker Analysis in HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

NCT06236269 is registered in ClinicalTrials.gov with SOLTI Breast Cancer Research Group as lead sponsor.

NCT NCT06236269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06236269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Biomarker Analysis in HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan
Lead sponsor
SOLTI Breast Cancer Research Group
Phase
Phase 2
Overall status
Recruiting
Start date
March 15, 2024
Completion date
February 20, 2027
Enrollment
50 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage iv